Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MIL93
i
Other names:
MIL93, recombinant humanized anti-Claudin 18.2 mab
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Beijing Mabworks Biotech
Drug class:
CLDN18.2 inhibitor
Related drugs:
‹
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AZD5863 (3)
AB011 (2)
ASP2138 (2)
TST001 (2)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
DR30303 (0)
FL-301 (0)
IBI-389 (0)
IBI360 (0)
LB4330 (0)
LM-102 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
QLS31905 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
AMG 910 (0)
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AZD5863 (3)
AB011 (2)
ASP2138 (2)
TST001 (2)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
DR30303 (0)
FL-301 (0)
IBI-389 (0)
IBI360 (0)
LB4330 (0)
LM-102 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
QLS31905 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
AMG 910 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
CLDN18.2 positive
Solid Tumor
CLDN18.2 positive
Solid Tumor
MIL93
Sensitive: C2 – Inclusion Criteria
MIL93
Sensitive
:
C2
MIL93
Sensitive: C2 – Inclusion Criteria
MIL93
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login